Last
Update:
July 30, 2015
 Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
K. Anstett, T. Mesplede, P. Quashie, et al
Abstract
Lack of clinically relevantd drug interactions between
elvitegravir plus ritonavir boosted-atazanavir and
telaprevir
J.M. Custodio, S. Guo, E.B. Lawson, et al
Abstract
Pharmacokinetics of boosted-elvitegravir in combination with
rifabutin, utilizing twice daily administration of
cobicistat to overcome induction
J.M. Custodio, Y. Shao, R. Begley, et al
Abstract
- Low
rates of integrase resistance for elvitegravir and raltegravir through week 96
in the phase 3 clinical study GS-US-183-0145
N.A. Margot, M. Rhee, J. Szwarcberg, M.D. Miller, et al
Abstract
-
Efficacy and safety
results from a randomized, double blind, active controlled trial of
elvitegravir (once-daily) versus
raltegravir
(twice-daily) in treatment-experienced HIV-positive patients: long term
96-week data
R. Elion, J.-M. Molina, -R. Arribas-Lopez, et al
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
Analysis of
efficacy by baseline viral load: phase 3 study comparing
elvitegravir/cobicistat/emtricitabine/tenofovir DF (quad) versus
ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in
treatment-naïve HIV-1-positive subjects: week 48 results
E. DeJesus, J. Rockstroh, K. Henry, et al
Abstract
-
Analysis of
efficacy by baseline HIV RNA: week 48 results from a phase 3 study of
elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to
efavirenz/emtricitabine/tenofovir DF in treatment-naïve HIV-1-positive
subjects
P. Sax, E. De Jesus, A. Mills,, et al
Abstract
|
XX
International AIDS Conference
Elvitegravir
Main Page